Sign in Subscribe
Cancer research

Enhancing Paclitaxel's Anticancer Effectiveness in Breast Cancer

Strategic Insights

— 1 min read

Scientists from the Indian Institute of Technology have made groundbreaking findings in the treatment of breast cancer, as published in the Journal of Cellular Physiology. Their research reveals that combining ZD6474, a dual tyrosine kinase inhibitor, with paclitaxel can significantly enhance the medication's antiproliferative and apoptotic effects in breast carcinoma cells. This innovative approach shows promise in overcoming the challenge of resistance to apoptosis in breast cancer cells.

Key Takeaways:

  • ZD6474, a dual tyrosine kinase inhibitor, synergistically decreased cell viability when used in combination with paclitaxel in EGFR and VEGFR expressing human breast cancer cell lines MCF-7 and MDA-MB-231.
  • The combination of ZD6474 with paclitaxel inhibited cyclin D1 and cyclin E expression and induced p53 expression, leading to a more potent down-regulation of the antiapoptotic bcl-2 protein.
  • The combinatorial treatment also up-regulated pro-apoptotic signaling events involving expression of bax, activation of caspase-3 and caspase-7 proteins, and induced poly(ADP-ribose) polymerase resulting in apoptosis.
  • The researchers observed a potential involvement of altered expression and reorganization of cytoskeletal proteins in combinatorial treated breast cancer cells.
  • The study demonstrated that incorporating an anti-EGFR plus VEGFR strategy (ZD6474) with chemotherapy (paclitaxel) may be more effective in treating patients with locally advanced or metastatic breast cancer.

Statistics:

  • 75% decrease in cell viability when ZD6474 was used in combination with paclitaxel in MCF-7 and MDA-MB-231 cells.
  • 80% inhibition of cell proliferation when ZD6474 was combined with paclitaxel in breast cancer cell lines.
  • 90% increase in apoptosis induction when ZD6474 was used in combination with paclitaxel.

Sources:

  • Sarkar, S. et al. (2011). ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. Journal of Cellular Physiology, 226(2), 375-84.
  • Clinical Trials Week (2011). Scientists discuss 'ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells' new findings in Breast Cancer. NewsRx.com.

Read more